Compare Regeneron Pharmaceuticals Inc (REGN) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Star Bulk Carriers Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Star Bulk Carriers Corp trades at $26.72 (market cap $2.98B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 23.8× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays the higher dividend (3.86%). Which is the better fit depends on your goals.
| REGN | SBLK | |
|---|---|---|
Market Cap | $70.79B | $2.98B |
Sector | Health | Industrials |
52-Week High | $812.27 | $28.21 |
52-Week Low | $545.46 | $16.79 |
Enterprise Value | $64.74B | $3.67B |
Dividend Yield | 0.56% | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Star Bulk Carriers (SBLK) trades at $26.09, up 4.78% in the last session, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in Q4 2025 and Q1 2026, with Q2 2026 EPS expected at $0.96. Financials show improving profitability, with a net income margin of 13.01% in 2026, and a dividend of $0.50 paid in June 2026. Analyst consensus is bullish, with 14 buys out of 24 ratings.
SBLK's outlook is supported by robust free cash flow and a healthier balance sheet, but risks include spot rate volatility and broader market pressures. The stock offers potential for high dividend yields and earnings growth, though investor caution is warranted amid sector cyclicality and economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
